4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Akari Therapeutics, Plc (AKTX) operates in the Biotechnology industry and is headquartered in Tampa, United States with about 5 employees. Its market capitalization is roughly $22 million. In the fiscal year ended 2025-12-31, AKTX reported $0M in revenue and ($17M) in net income.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($12M) | ($17M) | ($17M) | ($23M) |
| Net Income | ($17M) | ($20M) | ($10M) | ($18M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — | — |
| Operating Income (EBIT) | ($5M) | ($4M) | ($3M) | ($2M) | ($3M) | — | — |
| Net Income | ($5M) | ($14M) | ($5M) | ($6M) | ($2M) | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $48M | $51M | $4M | $14M | — |
| Total Liabilities | $20M | $28M | $5M | $12M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AKTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms